Update on Notice of 2020 Full Year Results

Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2020 on Tuesday 22 June 2021. http://novacyt.com/wp-content/uploads/2021/06/Notice-of-Results-18.06.21-ENGLISH.pdf

Visit Page

Launch of two new PCR COVID-19 assays

Paris, France and Camberley, UK – 3 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of two new polymerase chain reaction (PCR) assays, expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 variant detection portfolios. http://novacyt.com/wp-content/uploads/2021/06/Novacyt-Launch-of-two-new-PCR-COVID-19-assays-final.pdf

Visit Page

Launch of VersaLab™ Portable

Paris, France and Camberley, UK – 26 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ portfolio with the launch of VersaLab™ Portable to provide an additional level of support in near-patient testing environments. http://novacyt.com/wp-content/uploads/2021/05/Expansion-of-VersaLab-final-ENGLISH-.pdf

Visit Page

DHSC Dispute Update

Paris, France and Camberley, UK – 21 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with the Department of Health and Social Care (“DHSC”). http://novacyt.com/wp-content/uploads/2021/05/Novacyt-DHSC-Dispute-update-ENGLISH.pdf

Visit Page

Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range

Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two

Visit Page

Novacyt to support UNICEF with donation of one million COVID-19 tests

Donation supports testing efforts to help ensure continued access to essential services for children and their families Paris, France and Camberley, UK – 4 May 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT; “Novacyt”), an international clinical diagnostics company, will donate one million COVID-19 polymerase chain reaction (PCR) tests to UNICEF to help contain

Visit Page

R&D and UK operational update

Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides

Visit Page

Update on Notice of 2020 Full Year Results

Paris, France and Camberley, UK – 22 April 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the announcement on 9 April 2021, the Company now intends to report its audited financial results for the year ended 31 December 2020 on 29 June 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-Notice-of-Results-22.04.21-ENGLISH.pdf

Visit Page

Trading Update

Paris, France and Camberley, UK – 9 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its supply contract with the UK Department of Health and Social Care (DHSC) and provides an unaudited trading update for the three months ended 31 March 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-trading-update-09.04.2021.pdf

Visit Page

Launch of CE-Mark test to detect multiple COVID-19 variants of concern

SNPsig® VariPLEX™ is able to detect six key mutations of SARS-CoV-2 using PCR genotyping in under two hours Paris, France and Camberley, UK – 24 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2 February 2021, the Company will  launch SNPsig®

Visit Page